Patients with advanced non-small cell lung cancer: Are research biopsies a barrier to participation in clinical trials?

Journal of Thoracic Oncology

Volumn 11, Issue 1, 2016, Pages 79-84

  Lim, Charles ^a   Sung, Mike ^a   Shepherd, Frances A ^a   Nouriany, Nazanin ^a   Sawczak, Magdalena ^a   Paul, Tuhina ^a   Perera Low, Nicole ^a   Foster, Andrea ^a   Zawisza, Dianne ^a   Feld, Ronald ^a   Liu, Geoffrey ^a   Leighl, Natasha B ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Barrier; Clinical trial; Non small cell lung cancer; Research biopsy

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); DETERIORATION; EXPERIMENTAL THERAPY; FEMALE; HUMAN; INFORMED CONSENT; LUNG BIOPSY; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PATIENT PARTICIPATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUMOR BIOPSY; ADOLESCENT; BIOPSY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT PARTICIPATION; PATIENT SELECTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84959339644     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.09.006     Document Type: Article

References (17)

1. Peppercorn J, Shapira I, Collyar D, et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010;28:2635-2640.
2. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
3. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.
4. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004-1012.
5. Kitazono S, Fujiwara Y, Tsuta K, et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. Clin Lung Cancer. 2015;16:385-390.
6. Olson EM, Lin NU, Krop IE, et al. The ethical use of mandatory research biopsies. Nat Rev Clin Oncol. 2011;8:620-625.
7. Cannistra SA. Performance of biopsies in clinical research. J Clin Oncol. 2007;25:1454-1455.
8. Agulnik M, Oza AM, Pond GR, et al. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol. 2006;24:4801-4807.
9. Helft PR, Daugherty CK. Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol. 2006;24:4793-4795.
10. El-Osta H, Hong D, Wheler J, et al. Outcomes of research biopsies in phase I clinical trials: the M. D. Anderson Cancer Center experience. Oncologist. 2011;16:1292-1298.
11. Peppercorn J. Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies. J Clin Oncol. 2013;31:1-2.
12. Manne S, Kashy D, Albrecht T, et al. Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers. Eur J Cancer Care (Engl). 2015;24:28-38.
13. Baggstrom MQ, Waqar SN, Sezhiyan AK, et al. Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials. J Thorac Oncol. 2011;6:98-102.
14. Lemech C, Dua D, Newmark J, et al. Patients' perceptions of research biopsies in phase I oncology trials. Oncology. 2015;88:95-102.
15. Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced non-small cell lung cancer. Ann Oncol. 2015;26:1415-1421.
16. Cheung CC, Martin BR, Asa SL. Defining diagnostic tissue in the era of personalized medicine. CMAJ. 2013;185:135-139.
17. Shiau CJ, Babwah JP, da Cunha Santos G, et al. Sample features associated with success rates in populationbased EGFR mutation testing. J Thorac Oncol. 2014;9:947-956.